Antidepressive Agents, Second-Generation
"Antidepressive Agents, Second-Generation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
| Descriptor ID |
D018687
|
| MeSH Number(s) |
D27.505.954.427.700.122.050
|
| Concept/Terms |
Antidepressive Agents, Second-Generation- Antidepressive Agents, Second-Generation
- Antidepressive Agents, Second Generation
- Second-Generation Antidepressive Agents
- Agents, Second-Generation Antidepressive
- Second Generation Antidepressive Agents
- Atypical Antidepressants
- Antidepressants, Atypical
- Antidepressive Drugs, Second-Generation
- Antidepressive Drugs, Second Generation
- Drugs, Second-Generation Antidepressive
- Second-Generation Antidepressive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antidepressive Agents, Second-Generation".
Below are MeSH descriptors whose meaning is more specific than "Antidepressive Agents, Second-Generation".
This graph shows the total number of publications written about "Antidepressive Agents, Second-Generation" by people in this website by year, and whether "Antidepressive Agents, Second-Generation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 3 | 3 | 6 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 2 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 2 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 3 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidepressive Agents, Second-Generation" by people in Profiles.
-
Network meta-analysis (NMA) of dextromethorphan-bupropion (AXS-05) efficacy and safety in major depressive disorder. Eur Neuropsychopharmacol. 2024 Sep; 86:18-19.
-
Prescribing Trend of Inappropriate Medications in Outpatient Clinics for Older Adults With Heart Failure in the United States: NAMCS 2012 to 2016. Am J Cardiol. 2021 08 01; 152:168.
-
A Prospective Study Evaluating the Effects of SSRI Exposure on Cardiac Size and Function in Newborns. Neonatology. 2019; 115(4):320-327.
-
Are There Effective Psychopharmacologic Treatments for PTSD? J Clin Psychiatry. 2018 12 18; 80(3).
-
Trazodone and Parkinsonism: The Link Strengthens. Clin Neuropharmacol. 2018 May/Jun; 41(3):106-108.
-
Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. Clin J Am Soc Nephrol. 2017 09 07; 12(9):1409-1417.
-
Polymorphisms of 5-HTT LPR and GN?3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial. Am J Gastroenterol. 2017 Jun; 112(6):903-909.
-
Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment. Psychopharmacology (Berl). 2017 Jun; 234(11):1769-1779.
-
Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram. Am J Geriatr Psychiatry. 2017 May; 25(5):512-519.
-
SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget. 2016 May 31; 7(22):33179-91.